Welcome to the Newsroom
22 June 2016
PRIMA BIOMED ANNOUNCES FIRST SAFETY, PHARMACOKINETICS AND IMMUNO-MONITORING DATA FROM PHASE IIB CLINICAL TRIAL OF IMP321
SYDNEY, AUSTRALIA - Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD), a leading immuno-oncology company, is pleased to announce initial safety data from the first cohort of patients in its Phase IIb AIPAC chemo-immunotherapy clinical study of Prima’s lead compound, IMP321.
Article as pdf